Treatment with dabrafenib (BRAF inhibitor), with or without trametinib (MEK inhibitor), has been proven successful as tumor agnostic therapy for solid cancers with a verified BRAF V600E mutation and is approved by the US Food and Drug Administration (FDA), but not by the EMA, as tumor agnostic therapy [133]. Here, MAP2K7 is linked to neoplasm.